The P53 pathway: What questions remain to be explored?

Cell Death and Differentiation

Volumn 13, Issue 6, 2006, Pages 1027-1036

  Levine, A J ^a   Hu, W ^a   Feng, Z ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Apoptosis; DNA damage; Feedback loops; Stress responses; The p53 pathway

Indexed keywords

APC PROTEIN; DNA; GENE PRODUCT; MYC PROTEIN; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F1;

APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL AGING; CELL COMMUNICATION; CELL CYCLE; CELL CYCLE ARREST; CELL DEATH; DNA DAMAGE; DNA REPAIR; FAMILIAL CANCER; GENE ACTIVITY; GENE CONTROL; GENE INACTIVATION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC REGULATION; HOMEOSTASIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STRESS;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CELL CYCLE PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; DNA; HUMANS; MUTATION; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-MDM2; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33646807832     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401910     Document Type: Review

References (80)

1. Lane DP and Crawford LV (1979) T antigen is bound to a host protein in SV40-transformed cells. Nature 278: 261-263.
2. Linzer DI and Levine AJ (1979) Characterization of a 54 K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17: 43-52.
3. Kress M, May E, Cassingena R and May P (1979) Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum. J. Virol. 31: 472-483.
4. DeLeo AB, Jay G, Appella E, Dubois GC, Law LW and Old LJ (1979) Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci. USA 76: 2420-2424.
5. Levine AJ, Finlay CA and Hinds PW (2004) P53 is a tumor suppressor gene. Cell 116 (2 Suppl): S67-S69 1 p following S69.
6. Robins H, Alexe G, Harris SL and Levine AJ (2005) The first twenty-five years of p53 research In 25 Years of p53 Research Hainaut P, Wiman KG (eds) Dordrecht: Springer pp. 1-26.
7. Vogelstein B, Lane D and Levine AJ (2000) Surfing the p53 network. Nature 408: 307-310.
8. Giaccia AJ and Kastan MB (1998) The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12: 2973-2983.
9. Gudkov AV and Komarova EA (2003) The role of p53 in determining sensitivity to radiotherapy. Nat. Rev. Cancer 3: 117-129.
10. Oren M (2003) Decision making by p53: Life, death and cancer. Cell Death Differ. 10: 431-442.
11. Soussi T (2005) The p53 pathway and human cancer. Br. J. Surg. 92: 1331-1332.
12. Harris SL and Levine AJ (2005) The p53 pathway: Positive and negative feedback loops. Oncogene 24: 2899-2908.
13. Feng Z, Zhang H, Levine AJ and Jin S (2005) The coordinate regulation of the p53 and mTOR pathways in cells. Proc. Natl. Acad. Sci. USA 102: 8204-8209.
14. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ and Thompson CB (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 18: 283-293.
15. Yang A, Kaghad M, Caput D and McKeon F (2002) On the shoulders of giants: P63, p73 and the rise of p53. Trends Genet. 18: 90-95.
16. McKeon F and Yang A (2005) p53, p63, and p73: Internecine relations? In 25 Years of p53 Research Hainaut P, Wiman KG (eds) Dordrecht: Springer pp. 209-222.
17. Monti O, Damalas A, Strano S and Blandino G (2005) p73, p63 and mutant p53: Members of protein complexs floating in cancer cells In 25 Years for p53 Research Hainaut P, Wiman KG (eds) Dordrecht: Springer pp. 223-232.
18. Hoh J, Jin S, Parrado T, Edington J, Levine AJ and Ott J (2002) The p53MH algorithm and its application in detecting p53-responsive genes. Proc. Natl. Acad. Sci. USA 99: 8467-8472.
19. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G, Hakem R and Benchimol S (2003) Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112: 779-791.
20. Doman D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, O'Rourke K, Koeppen H and Dixit VM (2004) The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429: 86-92.
21. Stommel JM and Wahl GM (2004) Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 23: 1547-1556.
22. Appella E and Anderson CW (2001) Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268: 2764-2772.
23. Xirodimas DP, Saville MK, Bourdon JC, Hay RT and Lane DP (2004) Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118: 83-97.
24. Brooks CL and Gu W (2003) Ubiquitination, phosphorylation and acetylation: The molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15: 164-171.
25. Xu Y (2003) Regulation of p53 responses by post-translational modifications. Cell Death Differ. 10: 400-403.
26. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N and Liu EA (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
27. McKinney K, Mattia M, Gottifredi V and Prives C (2004) p53 linear diffusion along DNA requires its C terminus. Mol. Cell 16: 413-424.
28. McKinney K and Prives C (2005) Regulation of p53 DNA binding In 25 Years of p53 Research Hainaut P, Wiman KG (eds) Dordrecht: Springer pp. 27-52.
29. Lowe SW and Sherr CJ (2003) Tumor suppression by Ink4a-Arf: Progress and puzzles. Curr. Opin. Genet. Dev. 13: 77-83.
30. Hemann MT and Lowe S (2005) p53 links tumor development to cancer therapy In 25 Years of p53 Research Hainaut P, Wiman KG (eds) Dordrecht: Springer pp. 339-352.
31. Lev Bar-Or R, Maya R, Segel LA, Alon U, Levine AJ and Oren M (2000) Generation of oscillations by the p53-Mdm2 feedback loop: A theoretical and experimental study. Proc. Natl. Acad. Sci. USA 97: 11250-11255.
32. Lahav G, Rosenfeld N, Sigal A, Geva-Zatorsky N, Levine AJ, Elowitz MB and Alon U (2004) Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat. Genet. 36: 147-150.
33. Momand J, Zambetti GP, Olson DC, George D and Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245.
34. Oliner JD, Kinzler KW, Meltzer PS, George DL and Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83.
35. Montes de Oca Luna R, Wagner DS and Lozano G (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206.
36. Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG and Lozano G (2001) Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet. 29: 92-95.
37. Tao W and Levine AJ (1999) Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc. Natl. Acad. Sci. USA 96: 3077-3080.
38. Boyd SD, Tsai KY and Jacks T (2000) An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat. Cell Biol. 2: 563-568.
39. Mayo LD and Donner DB (2001) A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. USA 98: 11598-11603.
40. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B and Hung MC (2001) HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3: 973-982.
41. Okamoto K, Li H, Jensen MR, Zhang T, Taya Y, Thorgeirsson SS and Prives C (2002) Cyclin G recruits PP2A to dephosphorylate Mdm2. Mol. Cell 9: 761-771.
42. Levine AJ, Feng Z, Mak T, You H and Jin S (2006) Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev. 20: 267-275.
43. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK and Lane DP (2005) p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 19: 2122-2137.
44. Chen J, Ruan H, Ng SM, Gao C, Soo HM, Wu W, Zhang Z, Wen Z, Lane DP and Peng J (2005) Loss of function of def selectively up-regulates \{Delta\)113p53 expression to arrest expansion growth of digestive organs in zebrafish. Genes Dev. 19: 2900-2911.
45. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW and Vogelstein B (1992) Definition of a consensus binding site for p53. Nat. Genet. 1: 45-49.
46. Feng Z, Jin S, Zupnick A, Hoh J, de Stanchina E, Lowe S, Prives C and Levine AJ (2005) p53 tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene 24: 1-7.
47. Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack DH and Levine AJ (2000) The transcriptional program following p53 activation. Cold Spring Harb. Symp. Quant. Biol. 65: 475-482.
48. Moll UM, Wolff S, Speidel D and Deppert W (2005) Transcription-independent pro-apoptotic functions of p53. Curr. Opin. Cell Biol. 17: 631-636.
49. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M and Green DR (2004) Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303: 1010-1014.
50. Donehower LA (2002) Does p53 affect organismal aging? J. Cell Physiol. 192: 23-33.
51. Budanov AV, Sablina AA, Feinstein E, Koonin EV and Chumakov PM (2004) Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 304: 596-600.
52. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR and Kley N (1995) Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646-649.
53. Kunz C, Pebler S, Otte J and von der Ahe D (1995) Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucl. Acids Res. 23: 3710-3717.
54. Zou Z, Gao C, Nagaich AK, Connell T, Saito S, Moul JW, Seth P, Appella E and Srivastava S (2000) p53 regulates the expression of the tumor suppressor gene maspin. J. Biol. Chem. 275: 6051-6054.
55. Dameron KM, Volpert OV, Tainsky MA and Bouck N (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584.
56. Amzallag N, Passer BJ, Allanic D, Segura E, Thery C, Goud B, Amson R and Telerman A (2004) TSAP6 facilitates the secretion of translationally controlled tumor protein/histamine-releasing factor via a nonclassical pathway. J. Biol. Chem. 279: 46104-46112.
57. Deng C, Zhang P, Harper JW, Elledge SJ and Leder P (1995) Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684.
58. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T and Hannon GJ (1995) Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552-557.
59. Vaziri C, Saxena S, Jeon Y, Lee C, Murata K, Machida Y, Wagle N, Hwang DS and Dutta A (2003) A p53-dependent checkpoint pathway prevents rereplication. Mol. Cell 11: 997-1008.
60. Wang XJ, Greenhalgh DA, Jiang A, He D, Zhong L, Brinkley BR and Roop DR (1998) Analysis of centrosome abnormalities and angiogenesis in epidermal-targeted p53172 H mutant and p53-knockout mice after chemical carcinogenesis: Evidence for a gain of function. Mol. Carcinog. 23: 185-192.
61. Passer BJ, Nancy-Portebois V, Amzallag N, Prieur S, Cans C, Roborel de Climens A, Fiucci G, Bouvard V, Tuynder M, Susini L, Morchoisne S, Crible V, Lespagnol A, Dausset J, Oren M, Amson R and Telerman A (2003) The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interacts with Nix and the Myt1 kinase. Proc. Natl. Acad. Sci. USA 100: 2284-2289.
62. Dumont P, Leu JI, Della Pietra III AC, George DL and Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33: 357-365.
63. Khrunin AV, Tarskaia LA, Spitsyn VA, Lylova OI, Bebyakova NA, Mikulich AI and Limborska SA (2005) p53 polymorphisms in Russia and Belarus: correlation of the 2-1-1 haplotype frequency with longitude. Mol. Genet. Genomics 272: 666-672.
64. Ohayon T, Gershoni-Baruch R, Papa MZ, Distelman Menachem T, Eisenberg Barzilai S and Friedman E (2005) The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br. J. Cancer 92: 1144-1148.
65. van Heemst D, Mooijaart SP, Beekman M, Schreuder J, de Craen AJ, Brandt BW, Slagboom PE and Westendorp RG (2005) Variation in the human TP53 gene affects old age survival and cancer mortality. Exp. Gerontol. 40: 11-15.
66. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G and Levine AJ (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602.
67. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, Tan W, Liu Z and Lin D (2005) The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res. 65: 9582-9587.
68. Rotter V, Schwartz D, Almon E, Goldfinger N, Kapon A, Meshorer A, Donehower LA and Levine AJ (1993) Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome. Proc. Natl. Acad. Sci. USA 90: 9075-9079.
69. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT and Jacks T (1995) A subset of p53-deficient embryos exhibit exencephaly. Nat. Genet. 10: 175-180.
70. Armstrong JF, Kaufman MH, Harrison DJ and Clarke AR (1995) High-frequency developmental abnormalities in p53-deficient mice. Curr. Biol. 5: 931-936.
71. Mitsumori K, Shimo T, Onodera H, Takagi H, Yasuhara K, Tamura T, Aoki Y, Nagata O and Hirose M (2000) Modifying effects of ethinylestradiol but not methoxychlor on N-ethyl-N-nitrosourea-induced uterine carcinogenesis in heterozygous p53-deficient CBA mice. Toxicol. Sci. 58: 43-49.
72. Baatout S, Jacquet P, Michaux A, Buset J, Vankerkom J, Derradji H, Yan J, Von Suchodoletz H, De Saint-Georges L, Desaintes C and Mergeay M (2002) Developmental abnormalities induced by X-irradiation in p53 deficient mice. In Vivo 16: 215-221.
73. Strong LC (20L3) General keynote: Hereditary cancer: lessons from Li-Fraumeni syndrome. Gynecol. Oncol. 88 (1 Part 2): S4-S7; discussion S11-S13.
74. Kinyamu HK and Archer TK (2003) Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression. Mol. Cell. Biol. 23: 5867-5881.
75. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L and Gu W (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107: 137-148.
76. Motta MC, Divecha N, Lemieux M, Karnel C, Chen D, Gu W, Bultsma Y, McBurney M and Guarente L (2004) Mammalian SIRT1 represses forkhead transcription factors. Cell 116: 551-563.
77. Kenyon C (2005) The plasticity of aging: Insights from long-lived mutants. Cell 120: 449-460.
78. Guarente L and Picard F (2005) Calorie restriction -the SIR2 connection. Cell 120: 473-482.
79. Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, Jhappan C, Higashimoto Y, He P, Linke SP, Quezado MM, Zurer I, Rotter V, Wink DA, Appella E and Harris CC (2003) Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc. Natl. Acad. Sci. USA 100: 143-148.
80. Valenti LM, Mathieu J, Chancerelle Y, De Sousa M, Levacher M, Dinh-Xuan AT and Florentin I (2005) High levels of endogenous nitric oxide produced after burn injury in rats arrest activated T lymphocytes in the first G1 phase of the cell cycle and then induce their apoptosis. Exp. Cell Res. 306: 150-167.